Drug Design, Development and Therapy

Dovepress
open access to scientific and medical research

Original Research

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Open Access Full Text Article

Promoting endothelial function by
S-nitrosoglutathione through the HIF-1Œ±/VEGF
pathway stimulates neurorepair and functional
recovery following experimental stroke in rats
This article was published in the following Dove Press journal:
Drug Design, Development and Therapy
17 April 2015
Number of times this article has been viewed

Mushfiquddin Khan 1
Tajinder S Dhammu 1
Fumiyo Matsuda 1,2
Mauhammad Baarine 3
Tejbir Singh Dhindsa 1
Inderjit Singh 1
Avtar K Singh 3,4
Department of Pediatrics, Medical
University of South Carolina,
Charleston, SC, USA; 2School
of Health Sciences, Kagoshima
University, Kagoshima, Japan;
3
Department of Pathology
and Laboratory Medicine, Medical
University of South Carolina,
Charleston, SC, USA; 4Ralph
H Johnson VA Medical Center,
Charleston, SC, USA
1

Correspondence: Avtar K Singh
Department of Pathology and Laboratory
Medicine, Medical University of South
Carolina, 513 Children‚Äôs Research
Institute, 173 Ashley Avenue, Charleston,
SC 29425, USA
Email singha@musc.edu
Mushfiquddin Khan
Department of Pediatrics, Medical
University of South Carolina, 508
Children‚Äôs Research Institute, 173 Ashley
Avenue, Charleston, SC 29425, USA
Tel +1 843 792 7991
Fax +1 843 792 3653
Email khanm@musc.edu

Introduction
Stroke is a leading cause of serious long-term disability and ranks fourth among all
causes of death in the United States.1 Following stroke, direct trauma causes necrotic

2233

submit your manuscript | www.dovepress.com

Drug Design, Development and Therapy 2015:9 2233‚Äì2247

Dovepress

¬© 2015 Khan et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution ‚Äì Non Commercial (unported,¬†v3.0)
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on
how to request permission may be found at: http://www.dovepress.com/permissions.php

http://dx.doi.org/10.2147/DDDT.S77115
Powered by TCPDF (www.tcpdf.org)

Background: For stroke patients, stimulating neurorepair mechanisms is necessary to reduce
morbidity and disability. Our previous studies on brain and spinal cord trauma show that exogenous treatment with the S-nitrosylating agent S-nitrosoglutathione (GSNO) ‚Äì a nitric oxide
and glutathione metabolite of the human body ‚Äì stimulates neurorepair and aids functional
recovery. Using a rat model of cerebral ischemia and reperfusion (IR) in this study, we tested
the hypothesis that GSNO invokes the neurorepair process and improves neurobehavioral functions through the angiogenic HIF-1Œ±/VEGF pathway.
Methods: Stroke was induced by middle cerebral artery occlusion for 60 minutes followed by
reperfusion in adult male rats. The injured animals were treated with saline (IR group, n=7),
GSNO (0.25 mg/kg, GSNO group, n=7), and GSNO plus the HIF-1Œ± inhibitor 2-methoxyestradiol (2-ME) (0.25 mg/kg GSNO + 5.0 mg/kg 2-ME, GSNO + 2-ME group, n=7). The groups
were studied for either 7 or 14 days to determine neurorepair mediators and functional recovery.
Brain capillary endothelial cells were used to show that GSNO promotes angiogenesis and
that GSNO-mediated induction of VEGF and the stimulation of angiogenesis are dependent
on HIF-1Œ± activity.
Results: IR injury increased the expression of neurorepair mediators HIF-1Œ±, VEGF, and
PECAM-1 and vessel markers to a limited degree that correlate well with significantly compromised neurobehavioral functions compared with sham animals. GSNO treatment of IR not only
remarkably enhanced further the expression of HIF-1Œ±, VEGF, and PECAM-1 but also improved
functioning compared with IR. The GSNO group also had a higher degree of vessel density than
the IR group. Increased expression of VEGF and the degree of tube formation (angiogenesis)
by GSNO were reduced after the inhibition of HIF-1Œ± by 2-ME in an endothelial cell culture
model. 2-ME treatment of the GSNO group also blocked not only GSNO‚Äôs effect of reduced
infarct volume, decreased neuronal loss, and enhanced expression of PECAM-1 (PÓÄ¨0.001),
but also its improvement of motor and neurological functions (PÓÄ¨0.001).
Conclusion: GSNO stimulates the process of neurorepair, promotes angiogenesis, and aids
functional recovery through the HIF-1Œ±-dependent pathway, showing therapeutic and translational promise for stroke.
Keywords: GSNO, IR, HIF-1Œ±, VEGF, motor function, subtle behavior, neuroprotection,
neurorepair, angiogenesis, S-nitrosylation, stroke

Dovepress

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Khan et al

neuronal death; however, even greater apoptotic neuronal
damage occurs hours and days later, caused by secondary
injury due to inflammation and oxidative stress.2 These secondary injury mechanisms hamper the neurorepair process,
leading to long-term chronic disabilities.3 Unfortunately,
proven effective therapy for neuroprotection/neurorepair
following stroke is presently not available, mainly because
of the biphasic (acute and chronic) nature of the disease
and limited understanding of the differential mechanisms
involved in these phases.4 For functional recovery, clinical
trials in human stroke show that neuroprotective drugs failed
due to the lack of efficacy in the chronic phase.5,6 Therefore,
an ideal therapy must ameliorate acute as well as chronic
phases of the injury by well-understood mechanisms.
Recently, we and others identified an S-nitrosylating
agent, S-nitrosoglutathione (GSNO),7,8 that provided robust
neurovascular protection and blood‚Äìbrain barrier (BBB)
repair in a rat model of experimental stroke.7,9,10 This neurovascular protection was not associated with free nitric
oxide (NO) donors.11 Later, we observed that GSNO was
equally effective in aiding functional recovery in a rat model
of ischemia and reperfusion (IR),12 spinal cord injury,13
and traumatic brain injury,14,15 indicating that GSNO could
improve functional recovery following central nervous system injury. GSNO also improved learning and memory in
a rat model of cerebral hypoperfusion, a vascular dementia
model for experimental Alzheimer disease,16 suggesting
that GSNO‚Äôs activities are associated with motor as well as
cognitive function recovery. However, GSNO‚Äôs neurorepair mechanisms following central nervous system injury
are not understood. The term ‚Äúneurorepair‚Äù refers to the
combination of neurochemical and cellular events, such as
stimulation of angiogenic mediators (eg, PECAM-1 and
vascular endothelial growth factor [VEGF]) and formation
of vessels, leading to regenerative repair, neurorestoration,
and functional recovery. In this study, we investigated the
mechanisms of GSNO-mediated stimulation of the neurorepair process with a focus on the hypoxia-inducible factor-1
alpha (HIF-1Œ±)/VEGF/angiogenesis pathway using a rat
model of experimental stroke.
GSNO directly regulates several angiogenic and neurorepair mediators, including stabilization of HIF-1Œ±17 and induction of neurorepair mechanisms.12 S-nitrosylation-mediated
stabilization of HIF-1Œ± has also been shown to protect against
myocardial injury via the VEGF/angiogenesis pathway in
GSNO reductase (GSNOR) knockout mice,18 indicating that
HIF-1 is a key player in the repair processes. These studies

2234

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

provide a rationale for investigating S-nitrosylation-mediated
modulation of HIF-1Œ± for neurorepair in stroke.
HIF-1 is a nuclear transcription factor characterized as
the master regulator of cellular oxygen homeostasis. HIF-1Œ±
is rapidly upregulated in response to hypoxia and is rapidly
degraded upon reoxygenation/reperfusion.19 It activates the
tissue survival pathways by inducing several key enzymes
involved in cell metabolism (GLUT), angiogenesis (VEGF,
VEGFR1, angiopoietin), and free radical scavenging (heme
oxygenase-1 [HO-1]). HIF-1Œ± knockout mice show impaired
vascular development and embryonic lethality, indicating
HIF-1‚Äôs protective role in vascular diseases.20 The HIF-1Œ±
pathway is deeply involved in both pathological (hypoxia)
and neurorepair (normoxia) pathways following stroke.21 The
HIF-1Œ± stabilizers/inducers, such as desferrioxamine (an iron
chelator approved for hemochromatosis treatment), promote
a number of survival pathways, including neuroprotection,
angiogenesis, and neurotrophins. These HIF-1Œ± stabilizers
also reduce brain infarctions when administered pre- or
post-stroke.21 Prolyl hydroxylase (PHD) inhibitors, such as
FG-4539, are presently in a Phase II anemia trial because of
their activity to stabilize HIF-1Œ±.22 However, inhibition of
HIF-1Œ± under hypoxic/ischemic conditions in the acute phase
of IR injury has also been reported to be neuroprotective.22
Under normoxic conditions, studies are lacking on direct
stabilization of HIF-1Œ± by secondary modification and the
induction of consequent protective genes. However, the
S-nitrosylation reaction has been shown to stabilize HIF-1
protein expression and activity in normoxic endothelial cells.23
It was also confirmed that, while GSNO stabilizes HIF-1Œ± by
S-nitrosylation, reactive oxygen species (peroxynitrite, superoxide) destabilize it.24 The GSNO/S-nitrosylation-mediated
stabilization of HIF-1Œ± has been shown to involve upstream
PI3K/Akt activity.25 GSNO also attenuates PHD activity during
normoxia and inhibits proteasomal degradation of HIF-1Œ±.26
GSNO is a natural component of the human body produced by the reaction of NO with glutathione (GSH) in the
presence of oxygen.27 GSNO executes its action mainly via
S-nitrosylation of target proteins.28 Under physiological
conditions, GSNO and S-nitrosylated proteins are present in blood and brain.29‚Äì32 The concentration of GSNO in
adult rat brain tissue is estimated to be 6‚Äì8 ŒºM.30 A study
on GSNO metabolism and its membrane crossing ability has been reported.33 Using an in vitro BBB model, we
have also reported GSNO crossing the cellular membrane.7
Studies have also reported that GSNO inhibits platelet
activation34 and protects both BBB integrity and epithelial

Drug Design, Development and Therapy 2015:9

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Dovepress

permeability.15,35 Similarly, exogenous administration of
GSNO36 also protects against cardiac ischemic injury,18,37
supporting the therapeutic potential of GSNO. Pharmacological inhibition of GSNOR has also been shown to improve
endothelial functions,38 indicating a protective role of GSNO
in neurovascular dysfunction-related diseases.
In this study, we demonstrate that GSNO-mediated
HIF-1Œ±/VEGF/PECAM-1-dependent mechanisms stimulate
activation of angiogenesis-associated mediators, leading
to increased vessel density and improved neurobehavioral
functions during the delayed phases after IR. GSNO, via the
stabilization of HIF-1Œ±, thereby confers improved long-term
outcomes with reduced IR injury and better functional recovery after stroke. The beneficial effects of GSNO are blocked
by the HIF-1Œ± inhibitor 2-methoxyestradiol (2-ME), thus
supporting the conclusion that GSNO-stimulated beneficial
effects are dependent on the activity of HIF-1Œ±.

Methods
Reagents
GSNO was purchased from World Precision Instruments
(Sarasota, FL, USA). 2-ME and all other chemicals and
reagents were purchased from Sigma-Aldrich Co. (St Louis,
MO, USA), unless stated otherwise.

Animals and experimental design
Animals were male Sprague Dawley rats (n=121) weighing
250‚Äì290 g at the time of surgery. All animals received
humane care in compliance with the Medical University
of South Carolina (MUSC)‚Äôs guidelines and the National
Research Council‚Äôs criteria for humane care. Animal procedures were approved by the MUSC Institutional Animal Care
and Use Committee. The animals were allowed to acclimatize
for 3‚Äì5 days before the experiments. They were randomly
divided into four groups: 1) IR for 7 and 14 days (IR group);
2) IR + GSNO treatment for 7 and 14 days (GSNO group);
3) IR + GSNO + 2-ME (GSNO + 2-ME group) for 7 days; and
4) sham-operated control without treatment (Sham group)
for 14 days. The number of animals used in each experiment
is indicated in Figures 1‚Äì7.

Middle cerebral artery occlusion
(MCAO) rat model and GSNO
treatment
Rats were anesthetized by ketamine hydrochloride (90 mg/kg
body weight) and xylazine (10 mg/kg body weight)
administered intraperitoneally. Stroke was induced by

Drug Design, Development and Therapy 2015:9

GSNO stimulates HIF-1Œ±/VEGF pathway

60-minute left middle cerebral artery occlusion (MCAO)
using an intraluminal filament as previously described. 11
Regional cerebral blood flow was monitored during the
occlusion and early reperfusion to ensure the obstruction
of blood flow, as previously described.11,12 Reperfusion was
established by withdrawal of the filament. After 7 or 14
days, animals were sacrificed with an overdose of Nembutal.
The brain, including the peri-infarct region, was sliced for
histological and immunohistochemical analyses, and 2,3,5triphenyltetrazolium chloride (TTC) staining.
In the GSNO group, GSNO (0.25 mg/kg body weight) in
saline (~250 ŒºL) was slowly infused by jugular vein cannulation
at 1 hour after reperfusion. From 1 day after MCAO and thereafter, the same dose of GSNO was gavage fed until 7 or 14 days
following IR. Physiological parameters did not alter after GSNO
treatment. Details of the study on physiologic parameters in IR
and GSNO-treated rats have been reported earlier.11 In GSNO +
2-ME group, GSNO was treated for 7 days as described above.
2-ME (5 mg/kg, intraperitoneally) administration to the GSNO
group was initiated 24 hours after the first dose of GSNO treatment and continued until the 7th day after IR.

Evaluation of ischemic infarct
Coronal sections (2 mm) were immersed in 1% solution
of TTC in phosphate-buffered saline (pH 7.4) at 37¬∞C for
15 minutes, as described previously.12 After staining, infarctions were measured using Scion Image software (Scion
Corp., Frederick, MD, USA). Total infarct area was multiplied by the thickness of the brain sections to obtain infarct
volume as described previously.7 To minimize the error introduced by edema and liquefaction after infarction, an indirect
method for calculating infarct volume was also used.39,40 The
non-infarcted area in the ipsilateral hemisphere was subtracted from that in the contralateral hemisphere, and infarct
volume was calculated using the following formula:
Contralateral hemispheric volume ‚àí
Ipsilateral non-infarcted volume
=
of infarct volume
Contralateral hemispheric volume
Corrected percentage

(1)

Evaluation of neurological score
and motor behavior
Animals in each group were evaluated for neurological
scores, subtle behavior (using body swing test), and motor
coordination and balance (using rotarod task) before and at
the 7th and 14th days after reperfusion. The body weight of

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)



2235

Dovepress

Khan et al

a

Sham

IR

b

GSNO

HIF-1Œ±

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

35
30
25
20
15
10
5
0

% of HIF-1Œ±positive area

A

50 ¬µM

a

b
HIF-1Œ±
Œ≤-actin
Sham

IR

GSNO

Sham

IR

GSNO

b

VEGF

0.2

30
25
20
15
10
5
0

Sham

E

a

Sham

IR

IR

GSNO

GSNO

b

PECAM-1

100 ¬µM

F

a

b
PECAM-1
Œ≤-actin
Sham

IR

GSNO

VEGF/Œ≤-actin

Œ≤-actin

Sham

IR

GSNO

+++

*

Sham

IR

GSNO

3
+++

2
1
0

% of PECAM-1positive area

VEGF

*

0.1

25

PECAM-1/Œ≤-actin

b

a

+++

0.3

50 ¬µM

D

GSNO

0.4

% of VEGFpositive area

a

IR

Sham

0.5

0

C

*

0.6

HIF-1Œ±/Œ≤-actin

B

+++

2.5

*
Sham

IR

GSNO

+++

20
15

**

10
5
0

Sham

IR

GSNO
+++

2
1.5

**

1
0.5
0

Sham

IR

GSNO

Figure 1 Photomicrographs of immunoreactivity (immunohistochemistry) and Western blots of HIF-1Œ±, VEGF, and PECAM-1 in the cortical peri-infarct area at 14 days after IR.
Notes: GSNO treatment of IR animals was performed for 14 days. While IR increased the expression of HIF-1Œ± (A and B and graphs of cell counts [b] and densitometry [b]),
VEGF (C and D and graphs of cell counts [b] and densitometry [b]), and PECAM-1 (E and F and graphs of cell counts [b] and densitometry [b]), GSNO treatment significantly
increased the expression further. Data are presented as mean ¬± standard deviation (n=7). *PÓÄ¨0.05, **PÓÄ¨0.01 versus Sham; +++PÓÄ¨0.001 versus IR. Label IR represents IR group
and label GSNO represents GSNO group.
Abbreviations: GSNO, S-nitrosoglutathione; IR, ischemia‚Äìreperfusion; Sham, sham-operated animals; VEGF, vascular endothelial growth factor; HIF-1Œ±, hypoxia-inducible
factor-1 alpha.

2236

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Drug Design, Development and Therapy 2015:9

Dovepress

b

Laminin

% of lamininpositive area

GSNO

30

% of GSL-1positive area

IR

Sham

a

20
15

% of Ki67positive area

A

GSNO stimulates HIF-1Œ±/VEGF pathway

b

GSL-1
200 ¬µM

C

a

b

Ki67
50 ¬µM

40
30
20
10
0

0

IR

Sham

*

10
5
0

IR

Sham

GSNO
+++

GSNO
+++

***
Sham

IR

GSNO

Figure 2 Photomicrographs of immunohistochemistry of blood vessel markers and cell proliferation marker at 14 days after IR.
Notes: Photomicrographs show that IR and GSNO treatment of IR increased the vessel density ([A] laminin [a] and laminin-positive cell counts [b], [B] GSL-1
[a] and GSL-1-positive cell counts [b]) in the peri-infarct area and (C) cell proliferation marker Ki67 (a) and Ki67-positive cell counts (b) in the peri-infarct area compared
with Sham. GSNO treatment significantly bolstered the expression compared with IR. Data are presented as mean ¬± standard deviation (n=3). *PÓÄ¨0.05, **PÓÄ¨0.01,***PÓÄÆ0.001
versus Sham; +++PÓÄ¨0.001 versus IR. Label IR represents IR group and label GSNO represents GSNO group.
Abbreviations: GSNO, S-nitrosoglutathione; IR, ischemia‚Äìreperfusion; Sham, sham-operated animals; GSL-1, Griffonia simplicifolia lectin 1.

B

35
30
25

***

20

4

Body swing score

Rotation speed (rpm)

A

15
10
5

***

3
2
1
0

0
Sham

C

400

Body weight (g)

300

IR

GSNO

*

Sham

IR

GSNO

D
12
10

200

mNSS

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

a

**

10

200 ¬µM

B

+++

20

100

8
6

*

4
2

0

0
Sham

IR

GSNO

Sham

IR

GSNO

Figure 3 Effect of GSNO on improvement of neurobehavioral functions at 14 days after IR.
Notes: Walking speed (rotarod) (A), body swing score (B), and body weight (C) were significantly increased/improved in the GSNO group compared with the IR group.
mNSS (D) was also improved in the GSNO group compared with the IR group. Data are presented as mean ¬± standard deviation (n=7). *PÓÄ¨0.05, ***PÓÄ¨0.001 versus IR.
Label IR represents IR group and label GSNO represents GSNO group.
Abbreviations: GSNO, S-nitrosoglutathione; IR, ischemia‚Äìreperfusion; mNSS, modified neurological severity score; Sham, sham-operated animals.

Drug Design, Development and Therapy 2015:9

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

2237

Dovepress

Khan et al

IR

Infarct volume (%)

B

GSNO

Walking time (s)

F

GSNO + 2-ME

200

***

150
100
50
0

Sham

IR

GSNO

GSNO

IR
IR

GSNO

GSNO + 2-ME

GSNO + 2-ME
1.4

HIF-1Œ±/Œ≤-actin

GSNO + 2-ME

Nissl

GSNO

50 ¬µM

***

1.2
1
0.8
0.6
0.4
0.2
0

IR

GSNO

GSNO +
2-ME

I

100

***

IR

GSNO

GSNO + 2-ME

PECAM-1

80
60
40
20
0
IR

GSNO

100 ¬µM

GSNO + 2-ME

E
3
2.5
2
1.5

***

1
0.5
Sham

IR

GSNO

GSNO +
2-ME

% PECAM-1-positive area

J

0

GSNO +
2-ME

Œ≤-actin

IR

Viable neurons (%)

250

HIF-1Œ±

***

H

D

300

G

80
70
60
50
40
30
20
10
0

C

Neurological score

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

A

25
20

***

15
10
5
0

IR

GSNO

GSNO + 2-ME

Figure 4 Effect of inhibition of HIF-1Œ± by 2-ME on GSNO-mediated protective effects at 7 days after IR.
Notes: While GSNO treatment blunts the deleterious effects of IR, 2-ME treatment reverses the effects of GSNO on brain infarctions (TTC [A]; infarct volume [B]),
neuronal viability (Nissl staining [C]; viable neuron counts [D]), neurobehavioral functions (neurological score [E]; walking time on rotarod [F]), expression of HIF-1Œ±
(Western blot [G]; densitometry [H]), and expression of PECAM-1 (immunohistochemistry [I]; cell counts [J]) in the peri-infarct area. GSNO treatment of IR animals was
performed for 7 days. Treatment with 2-ME was initiated 24 hours after IR and continued until day 7. Black arrows indicate neuronal degeneration and blue arrows show
viable neurons on Nissl staining (C). Data are presented as mean ¬± standard deviation (n=7). ***PÓÄ¨0.001 versus IR and/or GSNO + 2-ME. Label IR represents IR group, label
GSNO represents GSNO group and label GSNO+2-ME represents GSNO+2-ME group.
Abbreviations: 2-ME, 2-methoxyestradiol; GSNO, S-nitrosoglutathione; IR, ischemia‚Äìreperfusion; Sham, sham-operated animals; TTC, 2,3,5-triphenyltetrazolium chloride;
HIF-1Œ±, hypoxia-inducible factor-1 alpha.

2238

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Drug Design, Development and Therapy 2015:9

Dovepress

GSNO stimulates HIF-1Œ±/VEGF pathway

$

VL51$
*612

8QWU

6FU

$

%

$%

$%*612

+,)ƒÆ

»ïDFWLQ

%
+,)DDQG9(*)Œ≤DFWLQ

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

9(*)




ÔøΩÔøΩÔøΩ

+,)Œ±
9(*)











*612

8QWU

6FU

$

%

$% $%*612
VL51$

Figure 5 Effects of GSNO on expression of HIF-1Œ± and VEGF in HIF-1Œ±-silenced endothelial (bEnd3) cells.
Notes: Cells were seeded in 12-well plates. After 24 hours of culture, cells were transfected with two different HIF-1Œ± siRNAs (A: SC-44308 and B: SC-35562) using the
bEnd3 Standard Transfection protocol (CRL-2299; Altogen Biosystems, Las Vegas, NV, USA) for 72 hours. Transfected cells were treated with GSNO 100 ¬µM for 24 hours.
Cells were harvested and homogenized using RIPA buffer. (A) Western blot for HIF-1Œ±, VEGF, and Œ≤-actin. (B) Densitometry of HIF-1Œ± and VEGF normalized with Œ≤-actin.
Densitometry data are presented as mean ¬± standard deviation (n=5). ***PÓÄ¨0.001 versus Untr; +++PÓÄ¨0.001 versus siRNA A or siRNA B; $$$PÓÄ¨0.001 versus GSNO.
Abbreviations: GSNO, S-nitrosoglutathione; Scr, scrambled; Untr, untreated; VEGF, vascular endothelial growth factor; HIF-1Œ±, hypoxia-inducible factor-1 alpha; RIPA,
radioimmunoprecipitation assay.

each animal was determined before surgery and at days 7 and
14 after IR.
Neurological examination was performed by an observer
masked from the identity of the groups. A neurological
grading system with a 4-point scale (0‚Äì3), as described
previously,7 was used: 0, no observable neurological deficit
(normal); 1, failure to extend right forepaw on lifting the
whole body by tail (mild); 2, circling to the contralateral side
(moderate); and 3, leaning to the contralateral side at rest
or no spontaneous motor activity (severe). The animals not
showing paralysis at 1 hour after MCAO were excluded from
the study because the reduction of blood flow may not have
produced an infarction of adequate size to cause quantifiable
neurological deficits in those animals.
Modified neurological severity score (mNSS) measurement was performed as described previously.41 The test
is sensitive to unilateral cortical injury because it reflects

Drug Design, Development and Therapy 2015:9

multiple asymmetries, including postural, sensory, and
forelimb and hind limb use. A detailed description of this
functional test has been previously reported.42 In our studies,
mNSS was scaled from 0 to 12, with 0 as normal and 12 as
the maximal deficit.15
The body swing test reflects symmetry of striatal function.43
A normal rat typically has an equal number of swings to both
sides. Each rat was held along the vertical axis (defined as no
more than 10¬∞ to either the left or the right side) approximately
2.5 centimeters from the base of its tail and elevated 2.5 centimeters above a table surface. A swing was recorded whenever
the rat moved its head out of the vertical axis to either side. The
rats have to return to the vertical position for the next swing to
be counted. Thirty total swings (score 3) were counted.
In the motor coordination and balance test, rats were
examined on an accelerating rotarod task by trained personnel
blinded to animal groups as described previously.44 Walking

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

2239

Dovepress

Khan et al
0(

8QWU

*612

%

*6120(



ÔøΩÔøΩÔøΩ



WXEHIRUPDWLRQ

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

$










8QWU

0(

*6120(

Figure 6 Effect of GSNO on formation of capillary-like proangiogenic structures on endothelial cells.
Notes: bEnd3 endothelial cells were plated in a six-well Matrigel plate (BD Biocoat Matrigel Matrix, 354432). The cells were seeded at a density of 60,000 cells per well in
2 mL medium. Two hours after seeding on Matrigel, the cells were treated with GSNO, 2-ME, or GSNO followed by 2-ME (30 minutes later). The cells were observed under
microscope for formation of capillary-like structures at 3, 18, and 48 hours. Photographs are presented for the 48-hour study (A). Capillary-like structures (pink arrow) were
counted (B), and data are presented as mean ¬± standard deviation of % tube formation (n=5). ***PÓÄ¨0.001 versus Untr and 2-ME; +++PÓÄ¨0.001 versus GSNO.
Abbreviations: 2-ME, 2-methoxyestradiol; GSNO, S-nitrosoglutathione; Untr, untreated.

time and speed on rotarod was recorded as previously
described from our laboratory. 12 Speed was increased
from 0 rpm to 30 rpm, with an increment of 2 rpm every
5 seconds. Each rat was placed on the rotarod cylinder, and
the speed (rpm) at which the animal fell off the drum was
recorded. The trial ended if the animal fell off the drum. Each
animal was given three trials, and the mean speed (rpm) of
three trials was calculated for each animal.

2240

Powered by TCPDF (www.tcpdf.org)

*612

submit your manuscript | www.dovepress.com

Dovepress

Immunohistochemistry and histology
Paraffin-embedded sections from the formalin-fixed brain
tissues, processed at 7 or 14 days after reperfusion, were
stained using antibodies against angiogenesis markers/
mediators HIF-1Œ±, VEGF, and PECAM-1 (Santa Cruz
Biotechnology Inc., Dallas, TX, USA) and vessel markers laminin (Sigma-Aldrich Co.) and GSL-1 (Griffonia
simplicifolia lectin 1) (Vector Lab, Burlingame, CA, USA).

Drug Design, Development and Therapy 2015:9

Dovepress

GSNO stimulates HIF-1Œ±/VEGF pathway

)XQFWLRQDO
UHFRYHU\

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

*612

‚Ä¢9HVVHOGHQVLW\
‚Ä¢5HJHQHUDWLRQ
*612

+,)Œ±

‚Ä¢9(*)
‚Ä¢3(&$0

612

+,)Œ±

612
+,)»ïS&%3

7UDQVFULSWLRQ

Figure 7 Schematic showing GSNO-mediated events leading to neuroprotection and neurorepair as well as functional recovery.
Notes: S-nitrosylation by GSNO of HIF-1Œ± causes its stabilization, translocation to nucleus, and dimerization with HIF-1Œ≤, facilitating recruitment of p300/CBP and
transcribing neurorepair-related genes such as PECAM-1 and VEGF. They, in turn, stimulate the neurorepair process, leading to functional recovery.
Abbreviations: GSNO, S-nitrosoglutathione; VEGF, vascular endothelial growth factor; HIF-1Œ±, hypoxia-inducible factor-1 alpha; -SNO, S-nitrosocysteine proteins.

Cell proliferation was assessed using Ki67 (Abcam,
Cambridge, MA, USA). Secondary anti-rabbit and mouse
IgG, conjugated with Alexa Fluor 488, were incubated on
slides for 60 minutes. HIF-1Œ± and VEGF sections were
allowed to react with anti-mouse IgG conjugated to a
peroxidase-labeled dextran polymer and then developed
with diaminobenzidine substrate. All sections were examined for immunoreactivity in the peri-infarct area using an
Olympus microscope as previously described.9,14 Three areas
in the peri-infarct area of each immunostained section were
digitized by a 40√ó microscope objective with microscope
and camera without visual field overlap. Semiquantitative

Drug Design, Development and Therapy 2015:9

cell counting was performed using Scion Image software as
described previously.12
The degree of neuronal damage (loss of viable neurons) was
evaluated by cresyl violet (Nissl) staining. The staining highlights important structural features of neurons. The brain sections
described above were used to stain with Nissl, and the staining
was performed according to classical histology methods.12
Cells that contained Nissl substance were considered to be
viable neurons. Condensed fragmented staining shows neuronal
degeneration. The viable neurons were quantified by manually
counting cells with visible nucleoli, as described previously,45
in the peri-infarct area using an Olympus microscope.

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

2241

Dovepress

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Khan et al

Western blot analysis

Statistical evaluation

In the peri-infarct area from the ipsilateral injured brain tissue,
Western blot was performed using antibodies against HIF-1Œ±
and PECAM-1 (Abcam), VEGF (Santa Cruz Biotechnology
Inc.), and Œ≤-actin, as described earlier.9 Protein concentrations were determined using protein assay dye from Bio-Rad
Laboratories Inc. (Hercules, CA, USA). Densitometry of
protein expression was performed using a GS800 calibrated
densitometer from Bio-Rad Laboratories Inc.

Statistical analysis was performed as described previously50
using GraphPad Prism 5.01 software. Unless otherwise
stated, all values are expressed as mean ¬± standard deviation of n determinations or as mentioned. The results were
examined by unpaired Student‚Äôs t-test. Multiple comparisons were performed using the Kruskal‚ÄìWallis test, or
using analysis of variance followed by the Bonferroni test
as appropriate. A P-value less than 0.05 was considered
significant.

siRNA silencing of HIF-1Œ± expression
and treatment with GSNO in a mouse
brain capillary endothelial cell line
(bEnd3)
bEnd3, an immortalized mouse brain endothelial cell line
originally generated and characterized,46 and lately used in
our studies,47 is commercially available at American Type
Culture Collection ([ATCC] CRL-2299; Manassas, VA,
USA). It is a well-characterized endothelial cell line that
shows the expression of ICAM-1 and VCAM-1.47 Cells were
grown according to the supplier‚Äôs instructions and were
allowed to grow to ~70%‚Äì80% confluence. HIF-1Œ± expression was silenced for 72 hours by two different predesigned
siRNA sequence primers from Santa Cruz Biotechnology
Inc. (A: SC-44308 and B: SC-35562) and the corresponding scrambled siRNA (negative control) into the cells using
the bEnd3 standard transfection reagent (CRL-2299; Altogen Biosystems, Las Vegas, ND, USA) according to the
manufacturer‚Äôs instructions and as elsewhere described.48
Transfected cells were treated with freshly prepared GSNO
(100 ¬µM) for 24 hours. Western blots for HIF-1Œ± (ab65979;
Abcam), VEGF (SC507; Santa Cruz Biotechnology Inc.),
and Œ≤-actin (4967; Cell Signaling, Danvers, MA, USA)
were performed using 20 ¬µg protein samples.

Matrigel analysis
Matrigel assay was performed as described previously.49
Briefly, bEnd3 endothelial cells were plated in a six-well
Matrigel plate (BD Biocoat Matrigel Matrix, 354432). The
cells were seeded at a density of 105 cells per well in 2 mL
medium. At 2 hours after seeding in Matrigel, the cells were
treated with GSNO (100 ¬µM), 2-ME (5 ¬µM), or GSNO followed by 2-ME (30 minutes later). The cells were observed
under a microscope for formation of tube-like structures
at 3, 18, and 48 hours. Tubule length ratio, branch number
per field, and aggregation area were analyzed using ImageJ
software.

2242

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Results
GSNO treatment of IR for 2 weeks
enhanced the expression of angiogenic
mediators
Essential factors for the neurorepair process following
stroke include the transcriptional activity of HIF-1Œ± and
enhanced expression of the angiogenic factor VEGF along
with the endothelial cell proliferation mediator PECAM-1
(angiogenesis). S-Nitrosylation/GSNO has been shown to
stabilize HIF-1Œ±, leading to increased VEGF expression,
angiogenesis, and protection against myocardial injury.18
In this study, we observed that immunohistochemical
staining 14 days after IR shows an increased expression of
HIF-1Œ± (Figure 1A), VEGF (Figure 1C), and PECAM-1
(Figure 1E) in the peri-infarct area. GSNO treatment of IR
significantly increased the expression further of HIF-1Œ±,
VEGF, and PECAM-1. Similar results of increased expression in the GSNO group from the peri-infract area at the 14th
day after IR were confirmed for HIF-1Œ± (Figure 1B), VEGF
(Figure 1D), and PECAM-1 (Figure 1F) using Western blot.
In summary, GSNO treatment of IR increased the expression
of angiogenic mediators.

GSNO treatment of IR for 2 weeks
increased the number of blood vessels
and enhanced the expression of a cell
proliferation marker
Quantitatively comparing vessel density using markers for
vessels and a cell proliferation marker provides a measure
of angiogenic vessel formation.51 GSNO treatment of IR
for 2 weeks increased the expression of markers of vessel
density, including laminin (Figure 2A) and GSL-1 (Figure
2B), indicating that GSNO may have promoted new vessel
formation. Supporting the notion that the increased number
of vessels present in the peri-infarct area resulted from angiogenic processes, we determined the expression of Ki67, a

Drug Design, Development and Therapy 2015:9

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Dovepress

marker of cell proliferation. The expression of Ki67 (Figure
2C) was significantly increased in GSNO-treated animals
compared with IR animals. We anticipate that proliferating
cells include endothelial cells also because vessel density is
increased; however, we did not identify Ki67-positive cell
types in this study. Sham animals had significantly lower
expressions of angiogenic markers (Figure 2).

GSNO treatment of IR for 2 weeks
improved motor function and accelerated
the recovery of subtle behavior
Compromised neurobehavioral functions, especially motor
coordination and balance, and neurological functions are
the leading causes of disability and morbidity following
stroke. We determined the efficacy of GSNO in improving
motor and subtle behaviors. GSNO treatment significantly
improved tolerated rotation speed (rotarod task) (Figure 3A)
compared with the IR group measured at the 14th day after
IR. The treatment with GSNO also improved body swing
behavior (Figure 3B) and mNSS measured at day 14 after IR
(Figure 3D). The body weight of animals in the GSNO group
was also significantly improved compared with animals in
the IR group (Figure 3C).

Beneficial effects of GSNO on
neuroprotection and functional recovery
were blocked by HIF-1Œ± inhibitor 2-ME
2-ME is a natural metabolite of estradiol and has been documented to inhibit HIF-1Œ± stabilization and thus its transcriptional activity.52 Therefore, we investigated whether 2-ME
reverses GSNO‚Äôs HIF-1Œ±-dependent activities (Figure 4).
Administration of 2-ME to GSNO-treated animals for
6 days (first dose of 2-ME was administered 24 hours after
IR to investigate its effect after the acute phase) blocked
GSNO‚Äôs protective effect on brain infarctions and functional
recovery as evaluated by TTC staining (Figure 4A and B),
Nissl staining (Figure 4C and D), and neurological score
(Figure 4E). Furthermore, 2-ME treatment completely
blocked the beneficial effect of GSNO on motor function
recovery evaluated by rotarod performance (Figure 4F).
As expected, 2-ME treatment robustly inhibited HIF-1Œ±
protein expression (Figure 4G and H) as well as significantly reversed GSNO-mediated enhanced expression of
PECAM-1 (Figure 4I and J). Reversal of GSNO‚Äôs effect
by 2-ME was remarkably significant at day 7 after IR;
therefore, the experiment was stopped at the 7th day after
the injury.

Drug Design, Development and Therapy 2015:9

GSNO stimulates HIF-1Œ±/VEGF pathway

GSNO-mediated enhanced protein
expression of VEGF was reversed
by silencing HIF-1Œ± in endothelial cells
Stabilization of HIF-1Œ± results in increased HIF-1 transcriptional activity, leading to induction of HIF-1-dependent
genes, including angiogenic VEGF. GSNO treatment
resulted in greater protein expression of both HIF-1Œ± and
VEGF compared with untreated cells (Figure 5). Single
siRNA (A or B) silencing for HIF-1Œ± reduced the expression of HIF-1Œ± as well as VEGF; however, silencing with
both A and B siRNA remarkably reduced the expression
of HIF-1Œ± and VEGF. Moreover, cell transfection with
two HIF-1Œ±-targeted siRNAs markedly reduced GSNOmediated HIF-1Œ± stabilization and prevented the resultant
expression of VEGF (Figure 5), consistent with a role
of GSNO in HIF-1Œ± stabilization and the stimulation of
angiogenesis. However, a reduced level of both HIF-1Œ±
and VEGF in A + B + GSNO compared with A + B
set was unanticipated and may be attributed to the stability
of GSNO under bEnd3 cell transfection conditions.

GSNO-stimulated formation of capillarylike structures on endothelial cells was
blunted by the inhibition of HIF-1Œ±
We next examined the ability of GSNO to stimulate formation
and stabilization of tube/capillary-like proangiogenic structures on endothelial cultured cells using Matrigel (in vitro
angiogenesis). Tube/capillary-like proangiogenic structures
were significantly increased after 48-hour GSNO treatment
(Figure 6). Further, we assessed the effect of HIF-1Œ± inhibition using 2-ME on GSNO-stimulated capillary-like structure
formation. 2-ME is a specific HIF-1Œ± inhibitor and has been
widely used for the inhibition of angiogenesis.52 We observed
that GSNO‚Äôs capillary-like structure formation ability was
prevented by 2-ME, indicating that the GSNO-stimulated
proangiogenic process was mediated by HIF-1Œ± activity
(Figure 6).

Discussion
To facilitate functional recovery, an ideal stroke therapy must
ameliorate acute as well as chronic phases of the injury by wellunderstood mechanisms. Our previous studies showed that
GSNO treatment of IR provided neuroprotection in the acute
phase7,9 and improved neurobehavioral function in the chronic
phase.12 However, the mechanisms of GSNO-mediated stimulation of the neurorepair process require elucidation in order
to determine and then to widen its therapeutic potential.

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

2243

Dovepress

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Khan et al

Functional recovery in stroke is associated with vascular integrity and the stimulation of both angiogenesis and
neurogenesis.53 Stroke patients who have higher cerebral
blood vessel density recover better and survive longer than
patients who have lower vascular density.54 A low degree of
restorative angiogenesis after stroke results in limited and
insufficient functional recovery. However, angiogenesispromoting therapeutics confer not only a greater degree but
also a faster rate of functional improvement.55,56 Because
GSNO also produces effects that increase vessel density
(Figure 2) and enhance functional recovery (Figure 3),
GSNO likely promotes angiogenesis. 54 Findings from
other studies that observed GSNO-induced angiogenesis
in ischemic heart18 and in a cell culture model57 support
our observation of GSNO-mediated increased expression
of angiogenic markers (Figure 1) and a cell proliferation
marker (Figure 2C), as well as an increased number of vessels (Figure 2A and B).
The angiogenic marker VEGF is closely related to both
angiogenesis and neurogenesis.53 Increased neurogenesis
is accompanied by increased angiogenesis, whereas angiogenesis upregulates neurogenesis and NO-based drugs
upregulate both.58 Angiogenesis itself is regulated by VEGF,
mainly via HIF-1-based transcription. VEGF has been shown
to modulate coupling of angiogenesis and neurogenesis;
hence, it is an essential factor for regeneration.53,59 Therefore,
we investigated the effect of GSNO on VEGF as well as
PECAM-1 (markers of angiogenesis), finding that GSNO
increased the expression of both following IR (Figure 1).
This observation indicates that GSNO might be acting via the
upregulation of VEGF. VEGF is transcriptionally regulated
by HIF-1, and HIF-1Œ± is stabilized by GSNO.25,26 Figure 1
shows that GSNO increased the expression of and thereby
stabilized HIF-1Œ±. Consistent with our findings, endogenous
GSNO-induced stabilization of HIF-1Œ± via S-nitrosylation
was shown to induce the expression of VEGF, resulting in
angiogenesis and myocardial protection.18
A potential concern of GSNO‚Äôs impact on VEGF is
that HIF-1Œ±-dependent upregulation of VEGF has been
implicated in edema and BBB leakage in the acute phase
of IR and cerebral hemorrhage.60,61 For VEGF-mediated
BBB disruption to occur, MMP-9 and endothelial dysfunction are required.9,62 However, in addition to upregulating
VEGF, GSNO transcriptionally downregulated MMP-9 as
well as ICAM-1 and E-selectin, leading to reduced edema
and increased BBB protection in the acute phase of IR and
traumatic brain injury.9,15 Similarly, MMP-9-associated BBB
disruption in experimental diabetes has been prevented by
an exogenous treatment of GSNO.63 Exogenous inhibition
2244

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

of GSNOR and thus increased levels of GSNO have also
been reported to improve endothelial function.38 Decreased
levels of HIF-1Œ± in cerebrospinal fluid from hypoxic/
ischemic humans64 support the notion that HIF-1Œ±-mediated
mechanisms may ameliorate stroke injury. These observations indicate that HIF-1Œ± is likely an important beneficial
component of neuroprotection and the neurovascular repair
process.
To show that GSNO invokes its neurorestorative/neurorepair
effects via the HIF-1Œ±/VEGF pathway, as depicted in
Figure 7, we inhibited HIF-1Œ±, anticipating that it would
block the effect of GSNO on angiogenic mediators and functional recovery. The inhibition of HIF-1Œ± in GSNO-treated
animals reduced the expression of HIF-1Œ± (Figure 4G and
H) as well as PECAM-1 (Figure 4I and J), indicating that the
angiogenic effect of GSNO was dependent on the activity
of HIF-1Œ±. 2-ME treatment of GSNO animals also blunted
GSNO-mediated neuroprotection (Figure 4A‚ÄìD), decreased
neurological score (Figure 4E), and reduced motor function
recovery (Figure 4F). These findings support the protective role of HIF-1Œ±. Furthermore, endothelial cell culture
studies showing reduced tube formation (Matrigel assay for
angiogenesis) by 2-ME in GSNO-treated cells (Figure 6)
provide evidence that GSNO‚Äôs regenerative repair effects
are mediated by HIF-1Œ±/VEGF pathway-induced angiogenesis. Reduced VEGF expression in GSNO-treated HIF-1Œ±silenced cells (Figure 5) confirms that the GSNO-stimulated
VEGF/angiogenesis pathway is dependent on the transcriptional activity of HIF-1Œ±. Recently, stabilization of HIF-1Œ±
by N-acetylcysteine has been documented to provide neuroprotection in stroke,65 and its inhibition by 2-ME reduces
neuroprotection and downregulates neurorepair processes
in cerebral IR.65,66 2-ME has also been reported to worsen
outcomes after global ischemia.67 These observations further
suggest that GSNO-induced angiogenic and neurorestorative
processes are mediated through the stabilization of HIF-1Œ±.
The documented HIF-1Œ± stabilization by GSNO-mediated
S-nitrosylation (Cys-800) leading to stimulation of its transcriptional activity68 supports our finding of GSNO-mediated
enhanced transcriptional activity of HIF-1Œ± and the expression of VEGF (Figure 1). An enhanced level of GSNO has
been shown to stimulate the HIF-1Œ±-dependent angiogenic
process, protecting against cardiac ischemic injury.18,37
In view of the above observations, we hypothesized that
GSNO-mediated S-nitrosylation and stabilization of HIF-1Œ±
will enhance VEGF and PECAM-1, leading to increased
vessel density and functional recovery (Figure 7).
Both deficient S-nitrosylation and a reduction in NO
signaling pathways are observed in several neurodegenerative
Drug Design, Development and Therapy 2015:9

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Dovepress

disease processes, including stroke.9,69‚Äì72 These pathologies
occur due to decreased bioavailability of NO and, hence,
reduced biosynthesis of GSNO. We have previously documented reduced levels of NO and decreased expression of
S-nitrosocysteine proteins (-SNO) in the peri-infarct area.
This decreased -SNO was normalized by an exogenous
GSNO treatment.9 In short, reduced NO and -SNO are associated with IR pathophysiology. These observations are further
supported by a report showing decreased levels of plasma
NO and associated poor outcomes in stroke patients.73 Plasma
S-nitrosothiols are also decreased in patients with endothelial
dysfunction.74 These results indicate that S-nitrosylation is
reduced in IR; therefore, exogenous GSNO supplementation
in stroke therapy is a promising strategy. Although HIF-1Œ±
stabilization-based therapy using chemical inhibitors of
PHDs is under investigation in chronic ischemic diseases,
they also invoke HIF-1Œ±-independent effects.22 Therefore,
a direct stabilization by S-nitrosylation of HIF-1Œ± through the
endogenous signaling molecule GSNO is mechanistically a
more specific therapeutic approach especially for IR stroke
therapy. The role of the GSNO/HIF-1Œ±/VEGF pathway
in permanent ischemic stroke is less clear. Nonetheless,
evidence from clinical studies suggests that administration
of NO-based therapeutics in humans is safe and may be an
effective treatment for stroke injury in human subjects.75,76

Conclusion
GSNO-mediated HIF-1Œ± stabilization for neuroprotection and
the stimulation of the neurorepair process provides a novel
target mechanism for a therapy that could confer benefits in
both the acute and chronic phases of stroke. The translational
potential of GSNO is high because it occurs naturally in the
human body and its exogenous administration to humans is
not associated with any known side effects or toxicity. This
study shows the feasibility of a new treatment paradigm for
stroke, introducing the concept that stabilization of HIF-1Œ±
using GSNO may reduce disabilities in stroke survivors.

Acknowledgments
This work was supported by grants from NIH (NS-72511) and
VA merit award (BX001062). This work was also supported by
the NIH, Grants C06 RR018823 and No C06 RR015455 from
the Extramural Research Facilities Program of the National
Center for Research Resources. We thank Ms Joyce Bryan
and Ms Terry Hope for their technical help and ¬≠secretarial
assistance. We are grateful to Dr Harutoshi Sakakima and
Dr¬†Yoshihiro Yoshida for their valuable input. We also acknowledge Dr¬†Tom Smith and Dr Lisa Kerr from the MUSC Writing
Center for their valuable editing of the manuscript.
Drug Design, Development and Therapy 2015:9

GSNO stimulates HIF-1Œ±/VEGF pathway

Author background
M Khan (PhD) is a research associate professor at the MUSC
with a strong background in neuroprotection and functional
recovery in animal models of stroke, traumatic brain injury,
and spinal cord injury. He has published more than 80 articles
in the field of neuroprotection and neuropharmacology.
TS Dhammu (PhD) and M Baarine (PhD) are postdoctoral
fellows with expertise in cell culture and biochemical techniques. TS Dhammu has expertise in creating MCAO animal
model of stroke and evaluating neurobehavioral functions
of rodents. F Matsuda (PhD) is an assistant professor at the
Kagoshima University, Kagoshima, Japan, and she has a
strong background in evaluation of animals‚Äô neurobehavioral
functions. TS Dhindsa is a medical student at the MUSC and
works in our group on projects related to neurodegeneration.
He is an enthusiastic scientist with a special interest in
neuropharmacology of stroke and traumatic brain injury.
I Singh is a PhD and a distinguished university professor
and Scientific Director of the Children‚Äôs Research Institute
at the MUSC. He has published more than 280 articles in the
field of neuroprotection and functional recovery. AK Singh
is an MD and a practicing pathologist. She is professor at the
MUSC and Director of the Pathology Laboratory at the VA
Medical Center, Charleston, SC, USA. Her major research
interest is traumatic brain injury and neurodegenerative diseases including stroke and Alzheimer‚Äôs. She has published
more than 130 articles related to neurodegenerative diseases
in peer-reviewed journals.

Author contributions
This study is based on an original idea of M Khan and AK
Singh. All authors have contributed to conception and design
of the study, analysis and interpretation of data and drafting
the manuscript. Drs. TS Dhammu, F Matsuda, M Baarine,
M Khan and Mr. TS Dhindsa are responsible for acquisition
of data. All authors hereby approve the content of the article
and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References

1.	 Go AS, Mozaffarian D, Roger VL, et al; American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Heart disease
and stroke statistics ‚Äì 2014 update: a report from the American Heart
Association. Circulation. 2014;129(3):e28‚Äìe292.
2.	 Rosamond W, Flegal K, Furie K, et al; American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Heart disease
and stroke statistics ‚Äì 2008 update: a report from the American Heart
Association Statistics Committee and Stroke Statistics Subcommittee.
Circulation. 2008;117(4):e25‚Äìe146.
submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

2245

Dovepress

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Khan et al
	 3.	 Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms
in search of treatments. Neuron. 2010;67(2):181‚Äì198.
	 4.	 Maki T, Hayakawa K, Pham LD, Xing C, Lo EH, Arai K. Biphasic
mechanisms of neurovascular unit injury and protection in CNS diseases. CNS Neurol Disord Drug Targets. 2013;12(3):302‚Äì315.
	 5.	 Cramer SC. Repairing the human brain after stroke. II. Restorative
therapies. Ann Neurol. 2008;63(5):549‚Äì560.
	 6.	 Cramer SC. Repairing the human brain after stroke: I. Mechanisms of
spontaneous recovery. Ann Neurol. 2008;63(3):272‚Äì287.
	 7.	 Khan M, Sekhon B, Giri S, et al. S-Nitrosoglutathione reduces
inflammation and protects brain against focal cerebral ischemia in a
rat model of experimental stroke. J Cereb Blood Flow Metab. 2005;
25(2):177‚Äì192.
	 8.	 Liu DH, Yuan FG, Hu SQ, et al. Endogenous nitric oxide induces
activation of apoptosis signal-regulating kinase 1 via S-nitrosylation in
rat hippocampus during cerebral ischemia-reperfusion. Neuroscience.
2013;229:36‚Äì48.
	 9.	 Khan M, Dhammu TS, Sakakima H, et al. The inhibitory effect of
S-nitrosoglutathione on blood-brain barrier disruption and peroxynitrite
formation in a rat model of experimental stroke. J Neurochem. 2012;123
Suppl 2:86‚Äì97.
10.	 Yin XH, Yan JZ, Hou XY, Wu SL, Zhang GY. Neuroprotection of
S-nitrosoglutathione against ischemic injury by down-regulating
Fas S-nitrosylation and downstream signaling. Neuroscience. 2013;
248:290‚Äì298.
11.	 Khan M, Jatana M, Elango C, Paintlia AS, Singh AK, Singh I. Cerebrovascular protection by various nitric oxide donors in rats after
experimental stroke. Nitric Oxide. 2006;15(2):114‚Äì124.
12.	 Sakakima H, Khan M, Dhammu TS, et al. Stimulation of functional
recovery via the mechanisms of neurorepair by S-nitrosoglutathione
and motor exercise in a rat model of transient cerebral ischemia and
reperfusion. Restor Neurol Neurosci. 2012;30(5):383‚Äì396.
13.	 Chou PC, Shunmugavel A, El Sayed H, et al. Preclinical use of
longitudinal MRI for screening the efficacy of S-nitrosoglutathione
in treating spinal cord injury. J Magn Reson Imaging. 2011;33(6):
1301‚Äì1311.
14.	 Khan M, Sakakima H, Dhammu TS, et al. S-nitrosoglutathione reduces
oxidative injury and promotes mechanisms of neurorepair following
traumatic brain injury in rats. J Neuroinflammation. 2011;8:78.
15.	 Khan M, Im YB, Shunmugavel A, et al. Administration of
S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled
cortical impact. J Neuroinflammation. 2009;6:32.
16.	 Won JS, Kim J, Annamalai B, Shunmugavel A, Singh I, Singh AK.
Protective role of S-nitrosoglutathione (GSNO) against cognitive
impairment in rat model of chronic cerebral hypoperfusion. J Alzheimers
Dis. 2013;34(3):621‚Äì635.
17.	 Kimura H, Ogura T, Kurashima Y, Weisz A, Esumi H. Effects of nitric
oxide donors on vascular endothelial growth factor gene induction.
Biochem Biophys Res Commun. 2002;296(4):976‚Äì982.
18.	 Lima B, Lam GK, Xie L, et al. Endogenous S-nitrosothiols protect against myocardial injury. Proc Natl Acad Sci U S A. 2009;
106(15):6297‚Äì6302.
19.	 Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol.
2006;70(5):1469‚Äì1480.
20.	 Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control
of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev.
1998;12(2):149‚Äì162.
21.	 Kasivisvanathan V, Shalhoub J, Lim CS, Shepherd AC, Thapar A,
Davies AH. Hypoxia-inducible factor-1 in arterial disease: a putative
therapeutic target. Curr Vasc Pharmacol. 2011;9(3):333‚Äì349.
22.	 Harten SK, Ashcroft M, Maxwell PH. Prolyl hydroxylase domain
inhibitors: a route to HIF activation and neuroprotection. Antioxid
Redox Signal. 2010;12(4):459‚Äì480.
23.	 Palmer LA, Gaston B, Johns RA. Normoxic stabilization of hypoxiainducible factor-1 expression and activity: redox-dependent effect of
nitrogen oxides. Mol Pharmacol. 2000;58(6):1197‚Äì1203.

2246

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

24.	 Wellman TL, Jenkins J, Penar PL, Tranmer B, Zahr R, Lounsbury KM.
Nitric oxide and reactive oxygen species exert opposing effects on the
stability of hypoxia-inducible factor-1alpha (HIF-1alpha) in explants
of human pial arteries. FASEB J. 2004;18(2):379‚Äì381.
25.	 Carver DJ, Gaston B, Deronde K, Palmer LA. Akt-mediated activation of
HIF-1 in pulmonary vascular endothelial cells by S-nitrosoglutathione.
Am J Respir Cell Mol Biol. 2007;37(3):255‚Äì263.
26.	 Metzen E, Zhou J, Jelkmann W, Fandrey J, Brune B. Nitric oxide
impairs normoxic degradation of HIF-1alpha by inhibition of prolyl
hydroxylases. Mol Biol Cell. 2003;14(8):3470‚Äì3481.
27.	 Singh SP, Wishnok JS, Keshive M, Deen WM, Tannenbaum SR. The
chemistry of the S-nitrosoglutathione/glutathione system. Proc Natl
Acad Sci U S A. 1996;93(25):14428‚Äì14433.
28.	 Hess DT, Stamler JS. Regulation by S-nitrosylation of protein posttranslational modification. J Biol Chem. 2012;287(7):4411‚Äì4418.
29.	 Stamler JS, Jaraki O, Osborne J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc
Natl Acad Sci U S A. 1992;89(16):7674‚Äì7677.
30.	 Kluge I, Gutteck-Amsler U, Zollinger M, Do KQ. S-nitrosoglutathione in
rat cerebellum: identification and quantification by liquid chromatographymass spectrometry. J Neurochem. 1997;69(6):2599‚Äì2607.
31.	 Bryan NS, Rassaf T, Maloney RE, et al. Cellular targets and mechanisms
of nitros(yl)ation: an insight into their nature and kinetics in vivo. Proc
Natl Acad Sci U S A. 2004;101(12):4308‚Äì4313.
32.	 Tsikas D, Sandmann J, Holzberg D, Pantazis P, Raida M, Fr√∂lich JC.
Determination of S-nitrosoglutathione in human and rat plasma by
high-performance liquid chromatography with fluorescence and
ultraviolet absorbance detection after precolumn derivatization with
o-phthalaldehyde. Anal Biochem. 1999;273(1):32‚Äì40.
33.	 Matsumoto A, Gow AJ. Membrane transfer of S-nitrosothiols. Nitric
Oxide. 2011;25(2):102‚Äì107.
34.	 Radomski MW, Rees DD, Dutra A, Moncada S. S-nitroso-glutathione
inhibits platelet activation in vitro and in vivo. Br J Pharmacol. 1992;
107(3):745‚Äì749.
35.	 Savidge TC, Newman P, Pothoulakis C, et al. Enteric glia regulate
intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology. 2007;132(4):1344‚Äì1358.
36.	 Rassaf T, Poll LW, Brouzos P, et al. Positive effects of nitric oxide
on left ventricular function in humans. Eur Heart J. 2006;27(14):
1699‚Äì1705.
37.	 Konorev EA, Tarpey MM, Joseph J, Baker JE, Kalyanaraman B.
S-nitrosoglutathione improves functional recovery in the isolated rat
heart after cardioplegic ischemic arrest-evidence for a cardioprotective
effect of nitric oxide. J Pharmacol Exp Ther. 1995;274(1):200‚Äì206.
38.	 Chen Q, Sievers RE, Varga M, et al. Pharmacological inhibition of
S-nitrosoglutathione reductase improves endothelial vasodilatory function in rats in vivo. J Appl Physiol (1985). 2013;114(6):752‚Äì760.
39.	 Matsuda F, Sakakima H, Yoshida Y. The effects of early exercise on
brain damage and recovery after focal cerebral infarction in rats. Acta
Physiol (Oxf). 2011;201(2):275‚Äì287.
40.	 Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C,
Sharp FR. A semiautomated method for measuring brain infarct volume.
J Cereb Blood Flow Metab. 1990;10(2):290‚Äì293.
41.	 Mahmood A, Goussev A, Lu D, et al. Long-lasting benefits after treatment of traumatic brain injury (TBI) in rats with combination therapy
of marrow stromal cells (MSCs) and simvastatin. J Neurotrauma.
2008;25(12):1441‚Äì1447.
42.	 Li Y, Chen J, Chen XG, et al. Human marrow stromal cell therapy
for stroke in rat: neurotrophins and functional recovery. Neurology.
2002;59(4):514‚Äì523.
43.	 Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral
parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism.
J Neurosci. 1995;15(7 Pt 2):5372‚Äì5378.
44.	 Monville C, Torres EM, Dunnett SB. Comparison of incremental
and accelerating protocols of the rotarod test for the assessment of
motor deficits in the 6-OHDA model. J Neurosci Methods. 2006;
158(2):219‚Äì223.

Drug Design, Development and Therapy 2015:9

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 129.215.141.98 on 05-Oct-2016
For personal use only.

Dovepress
45.	 Zhu Y, Bu Q, Liu X, Hu W, Wang Y. Neuroprotective effect of TAT14-3-3Œµ fusion protein against cerebral ischemia/reperfusion injury in
rats. PLoS One. 2014;9(3):e93334.
46.	 Montesano R, Pepper MS, M√∂hle-Steinlein U, Risau W, Wagner EF,
Orci L. Increased proteolytic activity is responsible for the aberrant
morphogenetic behavior of endothelial cells expressing the middle T
oncogene. Cell. 1990;62(3):435‚Äì445.
47.	 Prasad R, Giri S, Nath N, Singh I, Singh AK. GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte
interactions. Glia. 2007;55(1):65‚Äì77.
48.	 Bove PF, Hristova M, Wesley UV, Olson N, Lounsbury KM, van der
Vliet A. Inflammatory levels of nitric oxide inhibit airway epithelial cell
migration by inhibition of the kinase ERK1/2 and activation of hypoxiainducible factor-1 alpha. J Biol Chem. 2008;283(26):17919‚Äì17928.
49.	 He P, Philbrick MJ, An X, Wu J, Messmer-Blust AF, Li J. Endothelial differentiation gene-1, a new downstream gene is involved
in RTEF-1 induced angiogenesis in endothelial cells. PLoS One.
2014;9(2):e88143.
50.	 Jatana M, Giri S, Ansari MA, et al. Inhibition of NF-kappaB activation
by 5-lipoxygenase inhibitors protects brain against injury in a rat model
of focal cerebral ischemia. J Neuroinflammation. 2006;3:12.
51.	 Valable S, Montaner J, Bellail A, et al. VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1. J Cereb Blood Flow Metab.
2005;25(11):1491‚Äì1504.
52.	 Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat. 2003;6(6):355‚Äì361.
53.	 Lok J, Gupta P, Guo S, et al. Cell-cell signaling in the neurovascular
unit. Neurochem Res. 2007;32(12):2032‚Äì2045.
54.	 Wei L, Erinjeri JP, Rovainen CM, Woolsey TA. Collateral growth and
angiogenesis around cortical stroke. Stroke. 2001;32(9):2179‚Äì2184.
55.	 Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis,
and synaptogenesis after stroke. Ann Neurol. 2003;53(6):743‚Äì751.
56.	 Chen J, Cui X, Zacharek A, et al. Niaspan increases angiogenesis
and improves functional recovery after stroke. Ann Neurol. 2007;
62(1):49‚Äì58.
57.	 Kawasaki K, Smith RS Jr, Hsieh CM, Sun J, Chao J, Liao JK. Activation
of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis.
Mol Cell Biol. 2003;23(16):5726‚Äì5737.
58.	 Zhang RL, Zhang ZG, Chopp M. Targeting nitric oxide in the subacute
restorative treatment of ischemic stroke. Expert Opin Investig Drugs.
2013;22(7):843‚Äì851.
59.	 Teng H, Zhang ZG, Wang L, et al. Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after
stroke. J Cereb Blood Flow Metab. 2008;28(4):764‚Äì771.
60.	 Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase9 inhibition attenuates vascular endothelial growth factor-induced
intracerebral hemorrhage. Stroke. 2007;38(9):2563‚Äì2568.
61.	 Bauer AT, B√ºrgers HF, Rabie T, Marti HH. Matrix metalloproteinase-9
mediates hypoxia-induced vascular leakage in the brain via tight junction
rearrangement. J Cereb Blood Flow Metab. 2010;30(4):837‚Äì848.

GSNO stimulates HIF-1Œ±/VEGF pathway
62.	 Lee CZ, Xue Z, Hao Q, Yang GY, Young WL. Nitric oxide in vascular endothelial growth factor-induced focal angiogenesis and
matrix metalloproteinase-9 activity in the mouse brain. Stroke.
2009;40(8):2879‚Äì2881.
63.	 Aggarwal A, Khera A, Singh I, Sandhir R. S-nitrosoglutathione prevents blood‚Äìbrain barrier disruption associated with increased matrix
metalloproteinase-9 activity in experimental diabetes. J Neurochem.
Epub 2014 Sep 4.
64.	 Ke XJ, Zhang JJ. Changes in HIF-1Œ±, VEGF, NGF and BDNF levels
in cerebrospinal fluid and their relationship with cognitive impairment
in patients with cerebral infarction. J Huazhong Univ Sci Technolog
Med Sci. 2013;33(3):433‚Äì437.
65.	 Zhang Z, Yan J, Taheri S, Liu KJ, Shi H. Hypoxia-inducible factor 1
contributes to N-acetylcysteine‚Äôs protection in stroke. Free Radic Biol
Med. 2014;68:8‚Äì21.
66.	 Wang Z, Tsai LK, Munasinghe J, et al. Chronic valproate treatment
enhances postischemic angiogenesis and promotes functional recovery
in a rat model of ischemic stroke. Stroke. 2012;43(9):2430‚Äì2436.
67.	 Zhou D, Matchett GA, Jadhav V, Dach N, Zhang JH. The effect of
2-methoxyestradiol, a HIF-1 alpha inhibitor, in global cerebral ischemia
in rats. Neurol Res. 2008;30(3):268‚Äì271.
68.	 Yasinska IM, Sumbayev VV. S-nitrosation of Cys-800 of HIF-1alpha
protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett. 2003;549(1‚Äì3):105‚Äì109.
69.	 Schonhoff CM, Matsuoka M, Tummala H, et al. S-nitrosothiol
depletion in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A.
2006;103(7):2404‚Äì2409.
70.	 Ju TC, Chen SD, Liu CC, Yang DI. Protective effects of
S-nitrosoglutathione against amyloid beta-peptide neurotoxicity. Free
Radic Biol Med. 2005;38(7):938‚Äì949.
71.	 Rauhala P, Mohanakumar KP, Sziraki I, Lin AM, Chiueh CC.
S-nitrosothiols and nitric oxide, but not sodium nitroprusside, protect
nigrostriatal dopamine neurons against iron-induced oxidative stress
in vivo. Synapse. 1996;23(1):58‚Äì60.
72.	 Terpolilli NA, Moskowitz MA, Plesnila N. Nitric oxide: considerations
for the treatment of ischemic stroke. J Cereb Blood Flow Metab. 2012;
32(7):1332‚Äì1346.
73.	 Rashid PA, Whitehurst A, Lawson N, Bath PM. Plasma nitric oxide
(nitrate/nitrite) levels in acute stroke and their relationship with severity
and outcome. J Stroke Cerebrovasc Dis. 2003;12(2):82‚Äì87.
74.	 Heiss C, Lauer T, Dejam A, et al. Plasma nitroso compounds are
decreased in patients with endothelial dysfunction. J Am Coll Cardiol.
2006;47(3):573‚Äì579.
75.	 Roberts BW, Mitchell J, Kilgannon JH, Chansky ME, Trzeciak S. Nitric
oxide donor agents for the treatment of ischemia/reperfusion injury in
human subjects: a systematic review. Shock. 2013;39(3):229‚Äì239.
76.	 Pluta RM, Oldfield EH, Bakhtian KD, et al. Safety and feasibility of
long-term intravenous sodium nitrite infusion in healthy volunteers.
PLoS One. 2011;6(1):e14504.

Dovepress

Drug Design, Development and Therapy

Publish your work in this journal
Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design
and development through to clinical applications. Clinical outcomes,
patient safety, and programs for the development and effective, safe,
and sustained use of medicines are a feature of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very
quick and fair peer-review system, which is all easy to use. Visit
http://www.dovepress.com/testimonials.php to read real quotes from
published authors.

Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal

Drug Design, Development and Therapy 2015:9

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

2247

